Olanzapine (Zyprexa Relprevv) vs Perseris

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Perseris

Rights held by Indivior Pharmaceuticals, Inc.; US product discontinued

Approved in Schizophreniasmall molecule
Reliable signal

NCT02109562 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.

Reported efficacy

Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162) (met)

Result source: NCT02109562

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlanzapine (Zyprexa Relprevv)Perseris
PANSS total, change—Not posted · NCT00088491-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
7 other results
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
  • -1.2 vs -8.2 wk 24.14 · n 408 · Phase 3 · secondary NCT02203838
  • -1.2 vs -4.8 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -9.4 vs -8.2 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -2.4 vs -4.8 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -10 vs -8.2 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -8.3 vs -4.8 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838
CGI-S, change-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489-0.1 vs -0.3+0.2 vs placebowk 24.14 · n 408NCT02203838
7 other results
  • 0 vs -0.3 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -0.9 vs -0.5 120 mg · wk 8 · n 114 · Phase 3 · secondary NCT02109562
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
  • -0.4 vs -0.3 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.1 vs -0.3 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.3 vs -0.3 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -0.2 vs -0.3 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838
PANSS response—Not posted · NCT00088491—Not reported
PSP, change—Not posted · NCT00088491—Not reported
Relapse (% of patients)20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489—Not reported

PANSS total, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Perseris
-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
7 other results
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
  • -1.2 vs -8.2 wk 24.14 · n 408 · Phase 3 · secondary NCT02203838
  • -1.2 vs -4.8 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -9.4 vs -8.2 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -2.4 vs -4.8 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -10 vs -8.2 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -8.3 vs -4.8 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838

CGI-S, change

Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
Perseris
-0.1 vs -0.3+0.2 vs placebowk 24.14 · n 408NCT02203838
7 other results
  • 0 vs -0.3 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -0.9 vs -0.5 120 mg · wk 8 · n 114 · Phase 3 · secondary NCT02109562
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
  • -0.4 vs -0.3 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.1 vs -0.3 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.3 vs -0.3 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -0.2 vs -0.3 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838

PANSS response

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Perseris
—Not reported

PSP, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Perseris
—Not reported

Relapse (% of patients)

Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
Perseris
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Olanzapine (Zyprexa Relprevv): 4 of 4 rows · Perseris: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlanzapine (Zyprexa Relprevv)Perseris
Dropout rate
54.9%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
28.6%120 mgb
NCT02109562 · Phase 3 · combination
show 8 more results
22.4%90 mg
NCT02109562 · Phase 3 · combination
54.5%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
51.6%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
51.5%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
78.3%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
40%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
9.8%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
1.7%120 mgb
NCT02109562 · Phase 3 · combination
show 8 more results
0%90 mg
NCT02109562 · Phase 3 · combination
6.1%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.7%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
11.3%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.4%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
—120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Serious AEs
9.5%a
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
0.9%120 mgb
NCT02109562 · Phase 3 · combination
show 8 more results
0%90 mg
NCT02109562 · Phase 3 · combination
9.1%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.7%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
6.1%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
4.3%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
6.7%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence
120 mgb
injection site pain 22.2% (placebo 19.5%)
headache 15.4% (placebo 23.7%)
weight increased 12.8% (placebo 3.4%)
NCT02109562 · Phase 3 · combination
show 8 more results
90 mg
headache 17.4% (placebo 23.7%)
injection site pain 15.7% (placebo 19.5%)
weight increased 13% (placebo 3.4%)
NCT02109562 · Phase 3 · combination
120 mg
injection site pain 21.2% (placebo 7.1%)
injection site induration 9.1% (placebo 0%)
injection site nodule 9.1% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
90 mg
headache 12.9% (placebo 0%)
injection site pain 12.9% (placebo 7.1%)
insomnia 12.9% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
weight increased 14.7% (placebo 3.6%)
injection site pain 12.7% (placebo 7.1%)
injection site nodule 7.1% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
180 mg subcutaneous
upper respiratory tract infection 13%
blood prolactin increased 8.7%
decreased appetite 8.7%
NCT03978832 · Phase 4 · registry result, not featured evidence
120 mg
cough 20%
dyspepsia 20%
weight increased 20%
NCT01677377 · Phase 2 · registry result, not featured evidence
90 mg
weight increased 33.3%
headache 20%
dyspepsia 13.3%
NCT01677377 · Phase 2 · registry result, not featured evidence
60 mg
weight increased 26.7%
headache 20%
rash 20%
NCT01677377 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 14 further endpoints in the CSV export.

Perseris

PANSS Total -16.456 vs -9.219 placebo score @ 8wk120 mg
absolute change · score
NCT02109562 · Phase 3 · combination
show 7 more results
-2.4 vs -4.8 placebo score @ 4.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-9.4 vs -8.2 placebo score @ 24.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-15.367 vs -9.219 placebo score @ 8wk90 mg
NCT02109562 · Phase 3 · combination
-8.3 vs -4.8 placebo score @ 4.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-10 vs -8.2 placebo score @ 24.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -4.8 placebo score @ 4.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -8.2 placebo score @ 24.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Total -10.9 vs -20.2 placebo score @ 52wk120 mg
absolute change · score
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-12.5 vs -20.2 placebo score @ 52wk90 mg
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -20.2 placebo score @ 52wk
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.3 vs -1 placebo score @ 52wk120 mg
absolute change · score
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-0.5 vs -1 placebo score @ 52wk90 mg
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.2 vs -1 placebo score @ 52wk
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Total -0.2 score @ 0wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 2
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.9 score @ 1wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 8
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.7 score @ 2wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 15
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.4 score @ 3wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 22
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 4wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 29
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.5 score @ 7wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 50
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -2.9 score @ 8wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 3 Day 57
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 12wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 4 Day 85
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 1.6 score @ 16wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Day 113-EOS
NCT03978832 · Phase 4 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Perseris's landscape